Skip to main content
Signal8

Liminatus Pharma, Inc. (LIMN) Form 424B3 — Jun 3, 2026

$LIMNForm 424B3Filed Jun 3, 2026, 8:33 AM ET0001104659-26-069843Original filing

Liminatus Pharma, Inc. (LIMN) filed a prospectus supplement to amend its S-1 registration, reducing the exercise price of its warrants from $0.29 to $0.18 per share. This significant cut in the strike price reflects a decline in the company's stock value, which was last reported at $0.195 per share on June 2, 2026. The offering includes 8.27 million shares of common stock, 5.54 million pre-funded warrants, and 13.81 million warrants to purchase additional shares.

Key figures

Gross Proceeds
0
Offering Price
0.195
Shares Offered
13813000
Warrants Offered
13813000
Warrant Exercise Price
0.18
Placement Agent Warrants
690650
Pre Funded Warrants Offered
5543000
Prior Warrant Exercise Price
0.29
Last Reported Stock Price
0.195
Last Reported Warrant Price
0.09

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.